Given the anticipated prevalence of TP53/CDKN2A alterations in GATA-3 PTCL (≈50%), these findings may further suggest that GATA-3 expression itself is an adverse prognostic factor, irrespective of the underlying genetic landscape (or at least TP53/CDKN2A status). This evidence concerns the gene TP53 and mature T-cell and NK-cell non-Hodgkin lymphoma.